Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DZZ2 | ISIN: US2666055007 | Ticker-Symbol: DC8A
Tradegate
31.10.24
15:17 Uhr
1,240 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DURECT CORPORATION Chart 1 Jahr
5-Tage-Chart
DURECT CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
1,2101,26013:38
1,2101,27012:28

Aktuelle News zur DURECT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.09.H.C. Wainwright behält neutrales Rating für Durect-Aktien nach FDA-Treffen3
26.09.H.C. Wainwright maintains Neutral rating on Durect shares post FDA meeting4
25.09.DURECT CORP - 8-K, Current Report1
25.09.DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis130- Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a...
► Artikel lesen
14.08.DURECT files for $250M mixed securities shelf2
13.08.DURECT Corp. Q2 Loss Decreases, Beats Estimates-
13.08.DURECT GAAP EPS of -$0.12 beats by $0.05, revenue of $2.2M misses by $0.29M1
13.08.DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update78- FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design - Seeking...
► Artikel lesen
12.08.DURECT Q2 2024 Earnings Preview1
30.07.DURECT CORP - 8-K, Current Report1
28.06.DURECT CORP - 8-K, Current Report2
21.05.DURECT CORP - 8-K, Current Report2
21.05.DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis167DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif., May 21, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX),...
► Artikel lesen
14.05.DURECT Corporation (NASDAQ:DRRX) Q1 2024 Earnings Call Transcript1
14.05.Earnings call: DURECT Corporation reports Q1 2024 results2
13.05.DURECT GAAP EPS of -$0.25 misses by $0.03, revenue of $1.83M misses by $0.9M1
13.05.DURECT CORP - 8-K, Current Report1
13.05.DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update452- FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif....
► Artikel lesen
27.03.DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update85- Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif., March 27...
► Artikel lesen
04.03.DURECT Corporation: DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET Product Line in U.S. and Canada157Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1